Seeing Nonmelanoma Skin Cancers Through a New Lens: The Role and Place of Immunotherapy

Program Overview

Join our multidisciplinary experts for an interactive program offering privileged insights into the evolving nonmelanoma skin cancer (NMSC) treatment paradigm. Core topics include evidence-based strategies for identifying patients at increased risk for disease progression, pinpointing the evolution of advanced disease, and integrating immunotherapy as a key component of the armamentarium against advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). A patient panelist augments these insights by highlighting aspects of their own treatment journey.

Credit Expired

1.0 CE Credit(s)

Expires: June 30, 2023

Target Audience

This activity is intended for medical oncology and dermatology clinicians who manage patients with nonmelanoma skin cancer (NMSC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Identify patients with difficult-to-treat nonmelanoma skin cancer (NMSC) based on current staging systems, risk factors, and guidelines
Select appropriate immunotherapy for advanced NMSC based on available data and approved indications

Activity Faculty

Prof. Axel Hauschild, MD

Professor, Dermatology
Head of Dermato-oncology
Department of Dermatology
University of Kiel
Kiel, Germany

David M. Miller, MD, PhD, FAAD

Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Mass General Cancer Center
Boston, United States

Vishal Anil Patel, MD, FAAD, FACMS

Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
George Washington University School of Medicine & Health Sciences
Washington DC, United States

Provider Statement

This activity is provided by RMEI Medical Education, LLC

Supporter Statement

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 